18 November 2015 - Merck and Pfizer today announced that the US FDA has granted avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, breakthrough therapy designation for the treatment of patients with metastatic Merkel cell carcinoma who have progressed after at least one previous chemotherapy regimen.

For more details, go to: http://www.merckgroup.com/en/media/extNewsDetail.html?newsId=6F1C8093DF67B882C1257F010041D205&newsType=1